본문 바로가기 주메뉴 바로가기

Invest & Partner





We invite investors and strategic partners to join Onselex on our journey to transform cancer treatment and save tens of millions of lives worldwide.

To learn more about Onselex or discuss an investment or strategic partnership opportunity, please fill out the form below.

Oncology Nanomedicine Investment Overview

Onselex Pharmaceuticals Inc. has developed ONX-1006, a nanoparticle-based cancer treatment designed to concentrate paclitaxel (PTX), a chemotherapy drug, in tumors while protecting normal cells.

Supported by over 30 preclinical studies, ONX-1006 demonstrated 20% greater tumor reduction than Abraxane (current pancreatic cancer drug) at the same weekly PTX dose, with no side effects. ONX-1006 is IND-ready, with an initial Phase I/IIa trial planned for Stage IV pancreatic cancer.

Explore our Executive Summary and Investor Presentation. To contact Onselex, use the existing inquiry form below.

Investment & Strategic Partnership Inquiries

We welcome inquiries from investors, strategic partners, pharmaceutical companies, and other organizations interested in Onselex and ONX-1006.

Information submitted through this form is for general communication purposes only. Nothing on this page constitutes an offer to sell or a solicitation of an offer to buy securities.